Androgen deprivation therapy has no effect on Pim-1 expression in a mouse model of prostate cancer

Wang,Jiang; Li,Gang; Li,Bo; Song,Hualin; Shang,Zhiqun; Jiang,Ning; Niu,Yuanjie

doi:10.3892/ol.2017.6010

Androgen deprivation therapy has no effect on Pim-1 expression in a mouse model of prostate cancer

Authors:
- Jiang Wang
- Gang Li
- Bo Li
- Hualin Song
- Zhiqun Shang
- Ning Jiang
- Yuanjie Niu
View Affiliations

Affiliations: Department of Urology, Tianjin Institute of Urology, The Second Hospital of Tianjin Medical University, Tianjin 300211, P.R. China
Published online on: April 7, 2017 https://doi.org/10.3892/ol.2017.6010
Pages: 4364-4370

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to observe the dynamic changes of proto‑oncogene, serine/threonine kinase, Pim‑1 at the gene and protein level in a mouse model of prostate cancer following surgical castration. Using LNCaP cells to establish a subcutaneous xenograft model and orthotopic prostate cancer BALB/c nude mouse models, the xenograft models were divided into an androgen‑dependent prostate cancer group (ADPC), an androgen deprivation therapy (ADT) group and an androgen independent prostate cancer (AIPC) group. Reverse transcription‑polymerase chain reaction (RT‑PCR), RT‑quantitative PCR, ELISA and immunohistochemistry analyses were performed to compare the expression levels of Pim‑1, prostate‑specific antigen (PSA) and androgen receptor (AR) in tumor tissue of three subgroups. Agarose gel electrophoresis revealed that the RT‑PCR results of the ADPC (0.59±0.01) and AIPC groups (1.14±0.015) were significantly different when compared with the ADT group (0.62±0.026; P<0.05). As for RT‑qPCR, the ΔCq of Pim‑1 in the ADPC (6.15±0.34) and AIPC (4.56±0.23) groups were significantly different compared with the ADT group (5.11±0.21; P<0.05). Using 2‑ΔΔCq as a relative quantification method to analyze the data, the amplification products of Pim‑1 increased by 2.05 and 3.01 times in the ADT and AIPC groups, respectively. ELISA demonstrated the following: The serum concentration of PSA was 0 ng/ml in the control group, 0.48±0.025 ng/ml in the ADPC group and 0.87±0.023 ng/ml in the AIPC group, which were significantly different compared with the ADT group (0.17±0.032 ng/ml; P<0.01). Upon immunohistochemical staining, the protein expression levels of Pim‑1 and AR, respectively, were 0.017±0.0021 and 0.032±0.009 in the ADPC group, 0.024±0.0019 and 0.040±0.011 in the AIPC group, and 0.018±0.0013 and 0.019±0.006 in the ADT group. The protein levels of Pim‑1 and AR in the ADPC and AIPC groups were significantly different compared with the ADT group (P<0.01). In addition, an orthotopic prostate cancer animal model of ADT was successfully established in the current study, and further investigation revealed that ADT did not affect the expression of Pim‑1 at the gene or protein levels; thus, it is hypothesized that Pim‑1 may be important in the proliferation and differentiation of prostate cancer during ADT.

View Figures

View References

1	Cuypers HT, Selten G, Quint W, Zijlstra M, Maandag ER, Boelens W, van Wezenbeek P, Melief C and Berns A: Murine leukemia virus-induced T-cell lymphomagenesis: Integration of proviruses in a distinct chromosomal region. Cell. 37:141–150. 1984. View Article : Google Scholar : PubMed/NCBI
2	Song JH, Padi SK, Luevano LA, Minden MD, DeAngelo DJ, Hardiman G, Ball LE, Warfel NA and Kraft AS: Insulin receptor substrate 1 is a substrate of the Pim protein kinases. Oncotarget. 7:20152–20165. 2016.PubMed/NCBI
3	Natarajan K, Xie Y, Burcu M, Linn DE, Qiu Y and Baer MR: Pim-1 kinase phosphorylates and stabilizes 130 kDa FLT3 and promotes aberrant STAT5 signaling in acute myeloid leukemia with FLT3 internal tandem duplication. PLoS One. 8:e746532013. View Article : Google Scholar : PubMed/NCBI
4	Holder SL and Abdulkadir SA: PIM1 kinase as a target in prostate cancer: Roles in tumorigenesis, castration resistance, and docetaxel resistance. Curr Cancer Drug Targets. 14:105–114. 2014. View Article : Google Scholar : PubMed/NCBI
5	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
6	Siegel RL, Miller KD and Jemal A: Cancer Statistics, 2017. CA Cancer J Clin. 66:7–30. 2017. View Article : Google Scholar
7	Mizokami A and Namiki M: Reconsideration of progression to CRPC during androgen deprivation therapy. J Steroid Biochem Mol Biol. 145:164–171. 2015. View Article : Google Scholar : PubMed/NCBI
8	Wang Q, Li W, Zhang Y, Yuan X, Xu K, Yu J, Chen Z, Beroukhim R, Wang H, Lupien M, et al: Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer. Cell. 138:245–256. 2009. View Article : Google Scholar : PubMed/NCBI
9	Grasso CS, Wu YM, Robinson DR, Cao X, Dhanasekaran SM, Khan AP, Quist MJ, Jing X, Lonigro RJ, Brenner JC, et al: The mutational landscape of lethal castration-resistant prostate cancer. Nature. 487:239–243. 2012. View Article : Google Scholar : PubMed/NCBI
10	Robinson D, Van Allen EM, Wu YM, Schultz N, Lonigro RJ, Mosquera JM, Montgomery B, Taplin ME, Pritchard CC, Attard G, et al: Integrative clinical genomics of advanced prostate cancer. Cell. 161:1215–1228. 2015. View Article : Google Scholar : PubMed/NCBI
11	Shah N, Pang B, Yeoh KG, Thorn S, Chen CS, Lilly MB and Salto-Tellez M: Potential roles for the PIM1 kinase in human cancer-a molecular and therapeutic appraisal. Eur J Cancer. 44:2144–2151. 2008. View Article : Google Scholar : PubMed/NCBI
12	Rimon E, Sasson R, Dantes A, Land-Bracha A and Amsterdam A: Gonadotropin-induced gene regulation in human granulosa cells obtained from IVF patients: Modulation of genes coding for growth factors and their receptors and genes involved in cancer and other diseases. Int J Oncol. 24:1325–1338. 2004.PubMed/NCBI
13	Cibull TL, Jones TD, Li L, Eble JN, Baldridge Ann L, Malott SR, Luo Y and Cheng L: Overexpression of Pim-1 during progression of prostatic adenocarcinoma. J Clin Pathol. 59:285–288. 2006. View Article : Google Scholar : PubMed/NCBI
14	Brasó-Maristany F, Filosto S, Catchpole S, Marlow R, Quist J, Francesch-Domenech E, Plumb DA, Zakka L, Gazinska P, Liccardi G, et al: PIM1 kinase regulates cell death, tumor growth and chemotherapy response in triple-negative breast cancer. Nat Med. 22:1303–1313. 2016. View Article : Google Scholar : PubMed/NCBI
15	Xu J, Zhang T, Wang T, You L and Zhao Y: PIM kinases: An overview in tumors and recent advances in pancreatic cancer. Future Onco. 10:865–876. 2014. View Article : Google Scholar
16	He HC, Bi XC, Zheng ZW, Dai QS, Han ZD, Liang YX, Ye YK, Zeng GH, Zhu G and Zhong WD: Real-time quantitative RT-PCR assessment of PIM-1and hK2 mRNA expression in benign prostate hyperplasia and prostate cancer. Med Oncol. 26:303–308. 2009. View Article : Google Scholar : PubMed/NCBI
17	Chen WW, Chan DC, Donald C, Lilly MB and Kraft AS: Pim family kinases enhance tumor growth of prostate cancer cells. Mol Cancer Res. 3:443–451. 2005. View Article : Google Scholar : PubMed/NCBI
18	Xu Y, Zhang T, Tang H, Zhang S, Liu M, Ren D and Niu Y: Overexpression of PIM-1 is a potential biomarker in prostate carcinoma. J Surg Oncol. 92:326–330. 2005. View Article : Google Scholar : PubMed/NCBI
19	van der Poel HG, Zevenhoven J and Bergman AM: Pim1 regulate androgen-dependent survival signaling in prostate cancer cells. Urol Int. 84:212–220. 2010. View Article : Google Scholar : PubMed/NCBI
20	Ha S, Iqbal NJ, Mita P, Ruoff R, Gerald WL, Lepor H, Taneja SS, Lee P, Melamed J, Garabedian MJ and Logan SK: Phosphorylation of the androgen receptor by PIM1 in hormone refractory prostate cancer. Oncogene. 32:3992–4000. 2013. View Article : Google Scholar : PubMed/NCBI
21	Kim O, Jiang T, Xie Y, Guo Z, Chen H and Qiu Y: Synergism of cytoplasmic kinases in IL6-induced ligand-independent activation of androgen receptor in prostate cancer cells. Oncogene. 23:1838–1844. 2004. View Article : Google Scholar : PubMed/NCBI
22	Hsu JL, Leong PK, Ho YF, Hsu LC, Lu PH, Chen CS and Guh JH: Pim-1 knockdown potentiates paclitaxel-induced apoptosis in human hormone-refractory prostate cancers through inhibition of NHEJ DNA repair. Cancer Lett. 319:214–222. 2012. View Article : Google Scholar : PubMed/NCBI
23	Wang J, Kim J, Roh M, Franco OE, Hayward SW, Wills ML and Abdulkadir SA: Pim1 kinase synergizes with c-MYC to induce advanced prostate carcinoma. Oncogene. 29:2477–2487. 2010. View Article : Google Scholar : PubMed/NCBI
24	Morishita D, Katayama R, Sekimizu K, Tsuruo T and Fujita N: Pim kinases promote cell cycle progression by phosphorylating and down-regulating p27Kip1 at the transcriptional and posttranscriptional levels. Cancer Res. 68:5076–5085. 2008. View Article : Google Scholar : PubMed/NCBI
25	Holder S, Zemskova M, Zhang C, Tabrizizad M, Bremer R, Neidigh JW and Lilly MB: Characterization of a potent and selective small-molecule inhibitor of the PIM1 kinase. Mol Cancer Ther. 6:163–172. 2007. View Article : Google Scholar : PubMed/NCBI
26	Hu XF, Li J, Vandervalk S, Wang Z, Magnuson NS and Xing PX: PIM-1-specific mAb suppresses human and mouse tumor growth by decreasing PIM-1 levels, reducing Akt phosphorylation, and activating apoptosis. J Clin Invest. 119:362–375. 2009.PubMed/NCBI
27	Zemskova M, Sahakian E, Bashkirova S and Lilly M: The PIM1 kinase is a critical component of a survival pathway activated by docetaxel and promotes survival of docetaxel-treated prostate cancer cells. J Biol Chem. 283:20635–20644. 2008. View Article : Google Scholar : PubMed/NCBI
28	Nakagawa S and Cuthill IC: Effect size, confidence interval and statistical significance: A practical guide for biologists. Biol Rev Camb Philos Soc. 82:591–605. 2007. View Article : Google Scholar : PubMed/NCBI